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INTRODUCTION
According to a recent United States (U.S.)
national survey on drug use and health,
substance use disorders (SUDs) character-
ized by hazardous use of alcohol, non-
prescribed drugs, and illicit drugs are
common. In 2013, 22.7 million persons
(8.6% of persons aged 12 years or older)
needed treatment for an illicit drug or
alcohol-use problem (1). Drug use disor-
ders produce a wide variety of medical
problems and are important contribu-
tors to years of life lost due to disability
and preventable death (2). Yet, screening,
intervening, and treating SUDs have not
been embraced within general medical set-
tings (3). In fact, even though untreated
SUDs place individuals at substantially
greater risk for a wide range of diseases
and are a pervasive public health burden,
only approximately one-tenth of Ameri-
cans aged 12 years or older with SUDs
received treatment in 2013 (1). A main
obstacle to patient engagement in and initi-
ation of SUDs treatment is lack of motiva-
tion to seek out follow-up care. Motivation
to do so may be compromised by a lack of a
personalized-medicine approach, in which
patients are frequently only offered a sin-
gle or narrow set of care options, which
do not align with their individual needs.
A gap exists in research in medical set-
tings regarding how to effectively imple-
ment shared-decision making between
patients and their providers, concerning
how to tailor evidence-based care options
to personalized needs and preferences of
clients (4–6).
Converging research over the past
30 years indicates that core features of
SUDs comprise of a spectrum of neurobi-
ological components, which in 2014, I dis-
tilled into a shared-decision-making and
personalized/precision medicine frame-
work for SUD treatment, the ASPIRE
model (7). This integrative model stresses
the need for translational research on
how to most effectively optimize imple-
mentation of patient-centered care using
this model in general medical settings
and specialty SUD-treatment programs,
in a manner whereby patients have an
active role as partners in deciding with
their providers on treatment strategies
for evidence-based care tailored to their
risk categories and values (7). This pre-
cision medicine approach should be cus-
tomized to genetic, psychological, and
physiological profiles and environmen-
tal events that patients experience as
presenting an obstacle to their over-
all wellness and recovery (7). Accord-
ingly, treatment and follow-up care plans
should be matched with individual dis-
ease characteristics, which may enhance
motivation of patients to cease haz-
ardous substance use and associated health
risk behaviors (7). Thus, the ASPIRE
model uses as its foundational principle
shared-decision-making between patients
and healthcare providers to customize
personalized medical care to particular
neuroscience-research-grounded profiles,
psychiatric comorbidities, readiness to
change, risk categories, and problems that
individual patients report as most distress-
ing to their daily lives (7). Recent advances
in genomic and health information tech-
nologies [for instance, meaningful use of
electronic health record systems (EHRs),
telemedicine, mobile-health technologies,
EHRs-linked patient registries, EHRs-
linked genomic data and lifestyle infor-
mation, etc.] and bioinformatics methods
for analyzing EHRs-linked biomedical big-
data repositories should be leveraged
to accelerate rigorous big-data science
research on how to effectively implement
such a personalized-medicine framework
in general medical settings.
In circumstances where individual
patients are cognitively impaired and have
limited insight, such a shared-decision-
making approach to SUD treatment may
actively involve patients’ caregivers or other
family members, if patients consent to
their involvement in their medical care (4–
7). In such cases, family members may
be recruited to help ensure patients fol-
low through and adhere to their treatment
plan mutually agreed upon with their med-
ical provider. Systematic rigorous research
is needed using a shared-decision-making
approach to find more effective ways of
reducing the burden of SUD and enhanc-
ing quality of lives not only for individual
patients but also for their family members
affected by an individual’s SUD.
EVIDENCE GAPS AND RESEARCH
AREAS CONCERNING ASPIRE
FRAMEWORK FOR PATIENT-CENTERED
TREATMENT OF SUDs
For patients at the severe end of the
SUDs spectrum, below I illuminate needed
relapse-prevention research testing com-
bined evidence-based cognitive-behavioral
therapy and pharmacological-intervention
adjuncts targeting prominent components
in the ASPIRE framework. “A” in this
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framework denotes anhedonia/reward-
deficit and “S” a stressful state, refer-
ring to a sensitized brain anhedonia and
stress system following repeated heavy
drug use and during drug withdrawal
(8). This sensitized brain system pro-
duces deficits in responses of the brain to
rewarding stimuli and produces a nega-
tive emotional state, which drives contin-
ued drug-taking behavior (8). “P” denotes
a pathological lack of self-control to cut
down drug use despite negative impli-
cations, which involves impairments in
prefrontal–cortical cognitive regulation of
inhibitory behaviors to reduce drug taking.
Relevant to these phenotypes, recent con-
verging clinical-research findings suggest
an overlap among neurobiological events
mediating drug craving and relapse trig-
gered by stress and drug-predictive envi-
ronmental cues (9–13). Across various
SUDs (e.g., cocaine, opioid, and tobacco
use disorders), these findings indicate
adrenergic alpha-2 receptor agonists (e.g.,
guanfacine, clonidine, lofexidine) may have
promise for facilitating relapse prevention
by decoupling brain responses to stress
and drug-predictive cues from drug crav-
ing (9–12). Further, guanfacine is approved
by the U.S. Food and Drug Administra-
tion (FDA) for treating attention deficit
hyperactivity disorder (ADHD) in youth.
It has been shown to enhance cognitive
processes involved in response inhibition
and executive functioning, such as atten-
tion shifting, thereby facilitating cortical
regulatory control over inflexible behav-
iors associated with vulnerability to drug
seeking and taking in individuals with
SUDs (11, 14).
Based upon the above promising proof-
of-concept clinical studies, double-blind
placebo-controlled randomized clinical
trials (RCTs) are needed in treatment-
seeking populations to test whether guan-
facine or other adrenergic alpha-2 receptor
agonists may be effective as pharmacother-
apy adjuncts to augment efficacy of cur-
rently available evidence-based treatment
options, to enhance relapse prevention in
recently abstinent patients.
For instance, in the case of opiate-
use disorders, there are effective FDA-
approved medication-assisted treatment
(MAT) options (such as buprenorphine in
medical settings). However, even with these
treatment options, opiate-use relapse rates
remain high. Thus, comparative effective-
ness research is needed in general medical
settings to determine whether adrener-
gic alpha-2 receptor agonist adjuncts –
thought to work by different mechanisms
of action to reduce opiate use – enhance the
effectiveness of buprenorphine in relapse
prevention, compared with buprenorphine
alone.
It would be helpful for such RCTs
to follow the FDA guidance on enrich-
ment strategies for clinical trials to sup-
port approval of human drugs (15). For
example, patients at study intake could be
queried on whether they experience fre-
quent psychological distress from stress
or restlessness/impulsivity. This is because
adrenergic alpha-2 receptor agonists are
postulated to be beneficial in relapse pre-
vention by decoupling sensitized brain
responses to stress from drug craving,
reducing impulsivity, and enhancing cog-
nitive processes important for attention
shifting (11–14). If patients do report expe-
riencing such psychological symptoms, the
likelihood of detecting an efficacy sig-
nal may be improved by employing a
personalized-medicine approach in which
these patient subgroups would be included
in these relapse-prevention trials, since they
are likely to benefit most from these agents.
Furthermore, in the context of preci-
sion medicine, adaptive designs research
is needed to develop and test outpatient
treatment algorithms and actionable clin-
ical decision support for different patient
subgroups with opiate-use disorders, with
or without chronic pain, which incor-
porate shared-decision making practices
in improving their health outcomes and
reducing the risk of death from over-
dose and other opiate-use related negative
consequences.
“I”and“R”in the ASPIRE model denote
insomnia and restlessness, common SUDs
withdrawal symptoms following repeated
heavy drug use that patients find distress-
ing, increasing likelihood of relapse follow-
ing abstinence (16–20). Gabapentin is a
widely prescribed FDA-approved anticon-
vulsant medication, which reduces alpha-
2d-1 membrane trafficking and calcium
currents at voltage-gated calcium chan-
nels in regions involved in the brain’s
sensitized responses to stress following
repeated heavy drug use and withdrawal
(21, 22). Gabapentin has also been fre-
quently used off-label to reduce sleep
disturbances and restlessness. Recent clini-
cal research suggests gabapentin may have
promise in reducing alcohol and cannabis
use and craving in alcohol- and cannabis-
dependent individuals, as well as sleep
and mood disturbances (21, 22). Ran-
domized controlled trials are needed to
test gabapentin’s effectiveness in facilitat-
ing relapse prevention in recently abstinent
cannabis-use and/or alcohol-use disorder
treatment seekers, employing the FDA
guidance on enrichment strategies for clin-
ical trials to support approval of human
drugs (15). If patients report experiencing
sleep disturbances or restlessness impair-
ing their daily lives, they would be con-
sidered for such a RCT, which would
test effectiveness of gabapentin combined
with suitable evidence-based cognitive-
behavioral therapies to target these dis-
turbances, enhance duration of abstinence,
and prevent relapse.
In the ASPIRE model, “E” denotes
excessive preoccupation with seeking drug
reinforcement, compared with natural
reinforcers, after transition from volitional
to compulsive drug use, especially follow-
ing drug craving when an individual with
a SUD comes in contact with a drug-
associated environment. Convergent pre-
clinical research, using the reinstatement
model of drug relapse, suggests gluta-
mate signaling dysfunction in the meso-
corticolimbic dopamine system plays a
key role in this addictive process across
multiple substances of abuse, including
alcohol, cannabis, cocaine, nicotine, and
opiates (23). N -acetylcysteine is an N-
acetyl pro-drug of the naturally occurring
amino acid cysteine and is FDA-approved
as a mucolytic agent for bronchopul-
monary disorders (24). Preclinical research
indicates that N -acetylcysteine works to
reduce drug-environment-triggered rein-
statement of drug seeking for various drugs
of abuse (23). It may do so by normaliz-
ing imbalances in glutamate signaling and
associated pathophysiology in neuroplas-
ticity in the mesocorticolimbic dopamine
system, in part by reversing down-
regulation of glial–glutamate transporter-
1 (GLT-1) and metabotropic glutamate
receptor 2/3 (mGluR2/3) function (25, 26).
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The National Drug Abuse Treatment
Clinical Trials Network of the National
Institute on Drug Abuse (NIDA CTN)
is currently implementing a nationwide
placebo-controlled RCT evaluating efficacy
of N -acetylcysteine versus placebo, added
to contingency management, for cannabis
cessation in adults ages 18–50 years old.
The basis for this trial is positive find-
ings from a RCT in cannabis-dependent
adolescents, which found more than
twice greater odds of cannabis abstinence
during treatment with N -acetylcysteine
compared with placebo (27, 28). Since
basic research suggests that the mecha-
nism of action by which N -acetylcysteine
works may suit it as a relapse-prevention
agent, RCTs are also needed to test its
efficacy as a relapse-prevention adjunct
to evidence-based treatment options in
recently abstinent treatment seekers. Fur-
ther, pharmacological adjuncts need to be
tested, which operate by similar mech-
anisms to reverse brain-reward-system
down-regulation of GLT-1 and mGluR2/3
function and associated glutamate signal-
ing imbalances, but which have greater
potency, bioavailability, and membrane
permeability than N -acetylcysteine. For
instance, N -acetylcysteine amide (NACA)
is a more potent derivative with greater
bioavailability and membrane permeabil-
ity, which may translate into improved clin-
ical research use as a relapse-prevention
candidate (23, 29).
CONCLUSION
Relapse-prevention research is needed
in the above areas using a personal-
ized/precision medicine approach in which
medical decisions regarding treatment
options are tailored to patient subgroups’
disease profiles and risk categories. The
ASPIRE model for SUDs treatment takes
into account needs for instituting a shared-
decision approach over the course of
patient-centered care, addressing prefer-
ences and values of patients and their fam-
ilies (7). This framework calls for rigorous
systematic research on effectiveness of per-
sonalizing treatment to those phenotypes
that patients report as presenting distress-
ing problems to their daily lives, driving
their continued drug-taking behaviors, and
increasing likelihood of drug relapse (7).
The FDA guidance on enrichment strate-
gies for clinical trials to support approval of
human drugs (15) should be used to guide
the design of randomized controlled trials
in a manner matching interventions and
their mechanisms of action to personalized
needs of patients. It would be useful for
enrichment strategies to be implemented
in a manner whereby only subgroups most
likely to benefit from interventions’ pos-
tulated mechanism-of-action are included
at study intake, prior to randomization.
The likelihood of detecting an efficacy
signal may be improved following such
an approach. Clinical research programs,
such as NIDA’s National Drug Abuse Treat-
ment Clinical Trials Network (CTN), can
serve an important role in furthering
such studies. Existing health information
system infrastructures in practice-based
research networks and recent advances
in bioinformatics methods for analyzing
biomedical big-data repositories of large
patient cohorts should be leveraged to
help accelerate this line of personalized-
medicine research. This, in turn, could
lead to more cost-efficient enrollment of
patients into trials, increased recruitment
of providers to deliver interventions within
studies, and more efficient utilization of
EHRs, EHRs-linked genetic information,
mobile-health and telemedicine technolo-
gies, and EHRs-linked patient registries
(3, 7, 30).
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